Personalized Cancer Care. Realized.
Forging a Clearer Path to Cancer Treatments
Coronavirus: Peer reviewed article published on Allarity’s stenoparib and its potential as a treatment for SARS-CoV-2
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ First North, Allarity (ALLR: SS) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Q4 2020 Conference Call
Q4/Annual Report publication